CompletedPhase 2

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

United States200 participantsStarted 2006-12

Plain-language summary

This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.

Who can participate

Age range45 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men 45 years of age or older * Documented bladder outlet obstruction Exclusion Criteria: * History of urinary retention * Symptomatic and recurrent urinary tract infection (UTI)

What they're measuring

Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)

Timeframe: Baseline and Week 12

Change From Baseline to End of Treatment in Detrusor Pressure at Maximum Flow Rate (PdetQmax)

Timeframe: Baseline and Week 12

Trial details

NCT IDNCT00410514

SponsorAstellas Pharma Inc

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-08

Results submitted2012-08-02

View on ClinicalTrials.gov More Lower Urinary Tract Symptoms trials